Patents by Inventor Michelle I-Ching LIN

Michelle I-Ching LIN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Materials and methods for treatment of hemoglobinopathies
    Patent number: 11566236
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for creating permanent changes to the genome that can result in at least one deletion, insertion, modulation, or inactivation of a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: January 31, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Tirtha Chakraborty, Michelle I-Ching Lin
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20220211874
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: February 2, 2022
    Publication date: July 7, 2022
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-Ching Lin, Bibhu Prasad Mishra, Elizabeth Paik, Andrew Kernytsky, Todd Douglass Borland
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20190284542
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for creating permanent changes to the genome that can result in at least one deletion, insertion, modulation, or inactivation of a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: February 5, 2019
    Publication date: September 19, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Tirtha Chakraborty, Michelle I-Ching Lin
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20190201553
    Abstract: Materials and methods for treating a patient with a hemoglobinopathy, both ex vivo and in vivo, and materials and methods for deleting, modulating, or inactivating a transcriptional control sequence of a BCL11A gene in a cell by genome editing.
    Type: Application
    Filed: March 18, 2019
    Publication date: July 4, 2019
    Applicant: CRISPR Therapeutics AG
    Inventors: Chad Albert Cowan, Ante Sven Lundberg, Tirtha Chakraborty, Michelle I-ching Lin, Bibhu Prasad Mishra, Elizabeth Jae-eun Paik, Andrew Kernytsky, Todd Douglas Borland
  • MATERIALS AND METHODS FOR TREATMENT OF HEMOGLOBINOPATHIES
    Publication number: 20180273609
    Abstract: The present application provides materials and methods for treating hemoglobinopathies. More specifically, the application provides methods for producing progenitor cells that are genetically modified via genome editing to increase the production of fetal hemoglobin (HbF), as well as modified progenitor cells (including, for example, CD34+ human hematopoietic stem cells) producing increased levels of HbF, and methods of using such cells for treating hemoglobinopathies such as sickle cell anemia and ?-thalassemia.
    Type: Application
    Filed: November 4, 2016
    Publication date: September 27, 2018
    Applicant: CRISPR Therapeutics AG
    Inventors: Matthew Hebden PORTEUS, Melanie Ruth ALLEN, Chad Albert COWAN, Ante Sven LUNDBERG, Michelle I-Ching LIN, Jeffrey LI, Thao Thi NGUYEN